What we do Sun Pharmaceutical Industries Ltd is a global specialty generic pharmaceutical company with a diversified portfolio across chronic and acute therapies, including generics, branded generics, APIs and innovative medicines. |
Founded in 1,983 |
Market share Largest pharmaceutical company in India, 4th largest specialty generics globally, ranked 13th in US generics market with 8.3% market share in India. |
Problem solved Provides affordable, high-quality medicines addressing diverse therapeutic areas for chronic and acute conditions worldwide. |
Top clients or who we serve Serves global markets including India, US, emerging markets, healthcare professionals, hospitals, and consumers in over 100 countries (B2B and B2C). |
Key management - |
Our journey and innovations Started with 5 products in 1983, expanded via acquisitions (e.g., Taro, Ranbaxy), diversified into innovative medicines, and built R&D for complex generics and specialty products. |
Where we operate Operates in over 100 countries with 40 manufacturing sites across India, US, Canada, Israel, Europe, Asia, and Africa. |
Top products or what we offer Offers over 2000 pharmaceutical products including tablets, injectables, topical creams across psychiatry, cardiology, dermatology, oncology, ophthalmology, and more. |
Top brands Flagship brands include Ilumya (psoriasis), IlumyaTM, Winlevi (acne), BromSite (ocular), Odomzo (oncology), Cequa (dry eye), Absorica (acne), Sezaby (neonatal seizures). |
Raw materials needed Active pharmaceutical ingredients (APIs), intermediates, chemical compounds for drug formulation. |
Raw materials supplier Global suppliers of APIs and intermediates including in-house API manufacturing. |
Recurring vs cyclical contribution Majority of revenue is recurring from pharmaceutical sales across global markets with stable demand. |
Our industry position Global specialty generics leader with strong market share in India, US and emerging markets; expanding innovative medicine portfolio. |
Financial highlights FY25 consolidated revenue of Rs. 52578 crore with net profit of Rs. 10929 crore; consistent double-digit growth in sales and profitability. |
Geographical revenue split FY25 revenue splits: India 33%, USA 31%, Emerging Markets 18%, Rest of World 14%, API & others 4%. |
Order book - |
Whats driving growth Growth driven by innovative medicines, complex generics, expanded global footprint, strong R&D, strategic acquisitions, and regulatory approvals. |
Our future plans Focus on expanding innovative medicine pipeline, enhancing specialty portfolio, increasing market penetration, and sustainability initiatives. |
Our green promise Committed to sustainability with renewable energy sourcing, emission reductions, water conservation, and waste recycling programs. |
Our people and values Over 43,000 employees worldwide with focus on diversity, inclusion, safety, and development under 'Sunology' culture. |
Key challenges ahead Regulatory compliances, competitive generic markets, patent expiries, and global supply chain challenges. |
Interesting facts Ranks 13th in US generics; first Indian pharma company to be top-ranked in India; has 40 manufacturing facilities globally. |
Risks and strategy Mitigates regulatory and market risks through strong governance, diversified portfolio, continuous innovation, and strategic acquisitions. |
